X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (6) 6
hygiene (6) 6
medical or veterinary science (6) 6
preparations for medical, dental, or toilet purposes (6) 6
specific therapeutic activity of chemical compounds ormedicinal preparations (6) 6
statins (6) 6
cardiovascular disease (5) 5
humans (5) 5
index medicus (5) 5
monoclonal-antibody (5) 5
pcsk9 (5) 5
acute coronary syndrome (4) 4
alirocumab (4) 4
cardiac & cardiovascular systems (4) 4
cardiovascular (4) 4
cholesterol (4) 4
cholesterol, ldl - blood (4) 4
double-blind method (4) 4
female (4) 4
hypercholesterolemia (4) 4
low density lipoprotein (4) 4
male (4) 4
middle aged (4) 4
abridged index medicus (3) 3
acute coronary syndromes (3) 3
aged (3) 3
analysis (3) 3
antibodies (3) 3
antibodies, monoclonal - therapeutic use (3) 3
association (3) 3
cardiovascular risk patients (3) 3
diabetes (3) 3
drug therapy (3) 3
follow-up studies (3) 3
immunoglobulins (3) 3
lipoproteins (3) 3
low density lipoproteins (3) 3
patients (3) 3
proprotein convertase 9 - antagonists & inhibitors (3) 3
safety (3) 3
angina (2) 2
angina pectoris (2) 2
antibodies, monoclonal (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
anticholesteremic agents (2) 2
anticholesteremic agents - therapeutic use (2) 2
cardiology and cardiovascular system (2) 2
cardiovascular diseases - epidemiology (2) 2
cardiovascular diseases - prevention & control (2) 2
care and treatment (2) 2
cerebral infarction (2) 2
drug dosages (2) 2
efficacy (2) 2
endocrinology & metabolism (2) 2
evolocumab (2) 2
health risk assessment (2) 2
heart attacks (2) 2
heart diseases (2) 2
heterozygous familial hypercholesterolemia (2) 2
human health and pathology (2) 2
hypercholesterolemia - drug therapy (2) 2
hypolipidemic agents - therapeutic use (2) 2
injections, subcutaneous (2) 2
internal medicine (2) 2
ischemia (2) 2
kexin (2) 2
life sciences (2) 2
medical research (2) 2
medicine, experimental (2) 2
medicine, general & internal (2) 2
mortality (2) 2
myocardial infarction (2) 2
myocardial-infarction (2) 2
pooled analysis (2) 2
rationale (2) 2
reducing lipids (2) 2
risk (2) 2
statin therapy (2) 2
stroke (2) 2
subtilisin (2) 2
total events (2) 2
treatment outcome (2) 2
trials (2) 2
viral antibodies (2) 2
10021 (1) 1
10034 (1) 1
10072 (1) 1
10161 (1) 1
[ sdv.mhep.csc ] life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
[sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
[sdv.mhep]life sciences [q-bio]/human health and pathology (1) 1
[sdv]life sciences [q-bio] (1) 1
acute coronary syndrome - blood (1) 1
acute coronary syndrome - complications (1) 1
acute coronary syndrome - drug therapy (1) 1
adult (1) 1
antibodies; humans; antibodies, monoclonal; anticholesteremic agents; medicine (1) 1
anticholesteremic agents - administration & dosage (1) 1
anticholesteremic agents - adverse effects (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Full text | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1589 - 1590
In 10 clinical trials involving 4747 patients, among those who received the PCSK9 inhibitor alirocumab, antidrug antibodies developed in 5.1%, although no... 
TRIAL | MEDICINE, GENERAL & INTERNAL | HYPERCHOLESTEROLEMIA | Antibodies | Anticholesteremic Agents | Antibodies, Monoclonal | Humans | Clinical trials | Lipoproteins (low density) | Immunoglobulins | Low density lipoprotein | Cholesterol
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 989 - 996
Aim: This sub-analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in... 
clinical trial | cardiovascular disease | type 1 diabetes | type 2 diabetes | dyslipidaemia | TRIALS | DESIGN | RATIONALE | CARDIOVASCULAR RISK PATIENTS | PCSK9 | MONOCLONAL-ANTIBODY | PHASE-3 | STATINS | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ENDOCRINOLOGY & METABOLISM | POOLED ANALYSIS | Hyperlipidemias - blood | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Diabetes Complications - therapy | Serine Proteinase Inhibitors - therapeutic use | Cardiovascular Diseases - complications | Drug Therapy, Combination - adverse effects | Serine Proteinase Inhibitors - adverse effects | Healthy Lifestyle | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Hyperlipidemias - therapy | Hyperlipidemias - complications | Diabetes Complications - prevention & control | Hypolipidemic Agents - adverse effects | Serine Proteinase Inhibitors - administration & dosage | Double-Blind Method | Drug Administration Schedule | Hyperlipidemias - drug therapy | Risk Factors | Diabetes Complications - drug therapy | Combined Modality Therapy - adverse effects | Diabetes Complications - blood | Proprotein Convertase 9 - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Aged | Hypolipidemic Agents - therapeutic use | Cohort Studies | Type 2 diabetes | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Low density lipoproteins | Cardiac patients | Medicine, Experimental | Statins | Cardiovascular agents | Low density lipoprotein | Diabetes | Original
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 09/2017, Volume 120, Issue 6, pp. 931 - 939
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 13, pp. 1863 - 1863
  Conclusions Data do not suggest a relationship between ADA or NAb and ALI LDL-C lowering efficacy or safety, with the exception of increased injection site... 
Cardiovascular | Internal Medicine | Viral antibodies | Antibodies | Low density lipoproteins | Biopharmaceutics | Drug dosages | Immunoglobulins
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2015, Volume 65, Issue 10, p. A1370
  Conclusion: CHOICE II will provide novel ALI efficacy and safety data (including 150 mg Q4W dosing) on background FENO, EZE or diet. Since ~90% pts enrolled... 
Medicine, Experimental | Medical research | Care and treatment | Hypercholesterolemia | Statins | Drug therapy | Cardiovascular disease
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 989 - 996
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A13393 - A13393
IntroductionIn ODYSSEY OUTCOMES, first occurrence of coronary heart disease (CHD) death, myocardial infarction (MI), fatal/nonfatal ischemic stroke, or... 
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2019, Volume 73, Issue 4, pp. 387 - 396
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with... 
alirocumab | total events | acute coronary syndrome
Journal Article
Circulation, 07/2019, Volume 140, Issue 2, p. 103
Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not... 
Journal Article
Circulation, ISSN 0009-7322, 11/2016, Volume 134, Issue Suppl_1 Suppl 1, pp. A16611 - A16611
AimODYSSEY CHOICE I (NCT01926782) evaluated 300 mg alirocumab (ALI) every 4 weeks (Q4W) for 48 weeks in patients with hypercholesterolemia at moderate to... 
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 09/2016, Volume 5, Issue 9, p. n/a
Journal Article